In line with the observed differences in BIMEL expression noted above, the resistance-inducing effect showed a more pronounced trend in unmutated CLL towards resistance to venetoclax in comparison with the mutated subset, particularly for the stimulation with agonistic CD40 mAb (±XL) (Figure 5b). The gene discussed is BCL2L11; the disease is B-cell chronic lymphocytic leukemia.